# Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC

Source: https://onco.cc/trials/nct06031558/  
OnCo record `nct06031558` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial in lung cancer, run by Shouyao Holdings (Beijing) Co. LTD, active but no longer recruiting.

## Summary

Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC is a phase 3, interventional study registered as NCT06031558 by Shouyao Holdings (Beijing) Co. LTD, with a registry enrolment figure of 120 participants, started 2023-10-31 and due to reach its primary completion in 2025-04-10. Interventions recorded: SY-5007. Conditions listed: Non-Small Cell Lung Cancer. Primary outcome: Assessment of ORR by independent review committee (IRC).. Lung eligibility wording from the registry: "Histologically or cytologically confirmed diagnosis of locally advanced (with a tumor lesion that cannot be eradicated by surgery or radiotherapy as assessed by the investigators) or metastatic NSCLC". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT06031558
- Phase: 3
- Setting: A Phase III, Open-Label, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC.
- Sponsor: Shouyao Holdings (Beijing) Co. LTD
- Enrolled: 120

## Sources

- ClinicalTrials.gov NCT06031558: https://clinicaltrials.gov/study/NCT06031558

## Connected records

- cancers: [RET fusion-positive non-small-cell lung cancer](https://onco.cc/cancers/ret-fusion-nsclc/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06031558.json